Novartis antibody new drug Busizumab injection new indication declared for market in China
楚一帆
发表于 2024-10-12 11:45:08
149
0
0
On October 12th, the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced that Novartis' application for the listing of Busizumab injection has been accepted, but the specific indications have not yet been disclosed.
Public data show that brucizumab is a new generation of fundus disease treatment drug targeting to inhibit VEGF, which has previously been approved internationally for the treatment of wet age-related macular degeneration (wAMD, also known as nAMD) and diabetes macular edema (DME). In China, the first listing application for this product was accepted in August last year, and this is the second listing application for this product in China.
Busizumab has been approved for the treatment of nAMD and DME in dozens of countries worldwide, but in China, it has not yet received formal approval from the National Medical Products Administration. But Novartis' public information shows that it has previously been approved for clinical urgent use in designated medical institutions in the Greater Bay Area through the "Hong Kong Macau Medical Device Connect" policy. According to the official website of the China Drug Clinical Trial Registration and Information Disclosure Platform, Novartis has completed at least three Phase 3 clinical trials of buxolizumab in China.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Sanofi: New indications for dabitol have been given priority review by the US FDA
- Novo Nordisk: Positive progress made in reducing the risk of kidney disease with Smegglutide injections
- BeiGene: The first indication approved for tirizizumab in the United States
- Novo Nordisk Smegglutide Injection Approved for Weight Loss Indications in China
- Novo Nordisk Smegglutide Injection Approved for Weight Loss Indications in China
- Novo Nordisk Smegglutide Weight Loss Indications Approved in China, Next Battle is Capacity
- Eli Lilly and Predator Peptide Approved for Long term Weight Management Indications in China
- Dexmedetomidine monoclonal antibody adds new indications for advanced gastric cancer
-
11月21日、2024世界インターネット大会烏鎮サミットで、創業者、CEOの周源氏が大会デジタル教育フォーラムとインターネット企業家フォーラムでそれぞれ講演、発言したことを知っている。周源氏によると、デジタル教 ...
- 不正经的工程师
- 昨天 16:36
- 支持
- 反对
- 回复
- 收藏
-
アリババは、26億5000万ドルのドル建て優先無担保手形と170億元の人民元建て優先無担保手形の定価を発表した。ドル債の発行は2024年11月26日に終了する予定です。人民元債券の発行は2024年11月28日に終了する予定だ ...
- SOGO
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
スターバックスが中国事業の株式売却の可能性を検討していることが明らかになった。 11月21日、外国メディアによると、スターバックスは中国事業の株式売却を検討している。関係者によると、スターバックスは中国事 ...
- 献世八宝掌
- 前天 16:29
- 支持
- 反对
- 回复
- 收藏
-
【意法半導体CEO:中国市場は非常に重要で華虹と協力を展開】北京時間11月21日、意法半導体(STM.N)は投資家活動の現場で、同社が中国ウェハー代工場の華虹公司(688347.SH)と協力していると発表した。伊仏半導体 ...
- 黄俊琼
- 前天 14:29
- 支持
- 反对
- 回复
- 收藏